Capricor Therapeutics Investors Face Lead Plaintiff Deadline in Fraud Suit

The Law Offices of Frank R. Cruz initiated the action following claims that Capricor Therapeutics failed to disclose critical information concerning its BLA resubmission for Deramiocel. According to the complaint, the company modified its statistical analysis plan without prior FDA agreement, creating a concealed risk that clinical results would be deemed insufficient to prove the drug’s effectiveness for Duchenne muscular dystrophy.

Plaintiffs argue these omissions rendered public statements about the company's business prospects materially misleading. Shareholders wishing to participate in the litigation may contact the firm directly to discuss their legal standing. Those who do not take action remain part of the class as absent members, preserving their right to retain independent counsel or wait for further developments in the case.